74 related articles for article (PubMed ID: 9573681)
1. The parallel between CD45 expression and extra-medullary evolution in aggressive myeloma with high serum lactate dehydrogenase.
Cesana C; Giachetti R; Almici C; Garau D; Mangoni L; Pesci A; Carlo-Stella C
Haematologica; 1998 Mar; 83(3):276-9. PubMed ID: 9573681
[No Abstract] [Full Text] [Related]
2. Establishment of a CD45-positive immature plasma cell line from an aggressive multiple myeloma with high serum lactate dehydrogenase.
Hata H; Matsuzaki H; Sonoki T; Takemoto S; Kuribayashi N; Nagasaki A; Takatsuki K
Leukemia; 1994 Oct; 8(10):1768-73. PubMed ID: 7934174
[TBL] [Abstract][Full Text] [Related]
3. Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma.
Reid S; Yang S; Brown R; Kabani K; Aklilu E; Ho PJ; Woodland N; Joshua D
Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e190-6. PubMed ID: 20201998
[TBL] [Abstract][Full Text] [Related]
4. Lactate dehydrogenase production and release in a newly established human myeloma cell line.
Hatakeyama N; Daibata M; Nemoto Y; Ohtsuki Y; Taguchi H
Am J Hematol; 2001 Apr; 66(4):267-73. PubMed ID: 11279638
[TBL] [Abstract][Full Text] [Related]
5. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.
Moreau P; Robillard N; Avet-Loiseau H; Pineau D; Morineau N; Milpied N; Harousseau JL; Bataille R
Haematologica; 2004 May; 89(5):547-51. PubMed ID: 15136217
[TBL] [Abstract][Full Text] [Related]
6. Chronobiological circadian aspects of serum lactate dehydrogenase and serum thymidine kinase in monitoring multiple myeloma.
Pasqualetti P; Casale R; Collacciani A
Am J Hematol; 1996 Feb; 51(2):176-7. PubMed ID: 8579069
[No Abstract] [Full Text] [Related]
7. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
9. MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas.
Fujii R; Ishikawa H; Mahmoud MS; Asaoku H; Kawano MM
Br J Haematol; 1999 Apr; 105(1):131-40. PubMed ID: 10233376
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
11. [Studies on lactic dehydrogenase (LDH) anomaly (author's transl)].
Shoda T; Toda N; Shibata S
Rinsho Byori; 1975 Mar; 23(3):209-12. PubMed ID: 1172067
[No Abstract] [Full Text] [Related]
12. [A case of multiple myeloma with an aggressive course and multiorgan plasmocytic involvement].
Wyszecka-Polk I; Ciepłuch H; Izycka E; Hała-Burda K
Pol Arch Med Wewn; 1996 Nov; 96(5):479-83. PubMed ID: 9091859
[TBL] [Abstract][Full Text] [Related]
13. Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells.
Collette M; Descamps G; Pellat-Deceunynck C; Bataille R; Amiot M
Eur Cytokine Netw; 2007 Sep; 18(3):120-6. PubMed ID: 17823079
[TBL] [Abstract][Full Text] [Related]
14. [Plasmocytic pleural effusion disclosing multiple myeloma].
Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T
Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
Ribas C; Colleoni GW; Silva MR; Carregoza MJ; Bordin JO
Eur J Haematol; 2004 Nov; 73(5):311-7. PubMed ID: 15458509
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL
Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of abnormal enzyme activities--with special reference to LD].
Fujita K
Rinsho Byori; 1999 Feb; Suppl 109():140-9. PubMed ID: 10198589
[No Abstract] [Full Text] [Related]
18. Increased susceptibility to apoptosis in CD45(+) myeloma cells accompanied by the increased expression of VDAC1.
Liu S; Ishikawa H; Tsuyama N; Li FJ; Abroun S; Otsuyama KI; Zheng X; Ma Z; Maki Y; Iqbal MS; Obata M; Kawano MM
Oncogene; 2006 Jan; 25(3):419-29. PubMed ID: 16247487
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma.
Simonsson B; Brenning G; Källander C; Ahre A
Eur J Clin Invest; 1987 Aug; 17(4):336-9. PubMed ID: 3117570
[TBL] [Abstract][Full Text] [Related]
20. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
